The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2013
Filed:
Oct. 22, 2009
Drew M Pardoll, Brookeville, MD (US);
Ching-tai Huang, Taipei, TW;
Jonathan Powell, Baltimore, MD (US);
Charles Drake, Baltimore, MD (US);
Dario a Vignali, Germantown, TN (US);
Creg J Workman, Memphis, TN (US);
Drew M Pardoll, Brookeville, MD (US);
Ching-Tai Huang, Taipei, TW;
Jonathan Powell, Baltimore, MD (US);
Charles Drake, Baltimore, MD (US);
Dario A Vignali, Germantown, TN (US);
Creg J Workman, Memphis, TN (US);
The Johns Hopkins University, Baltimore, MD (US);
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
Abstract
Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.